Drug Trial Radar · NCT07281105
EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study
Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
131
Actual
Start
Aug 23, 2018
Primary completion
Aug 12, 2025
Study completion Aug 12, 2025
Sponsor
- Lead sponsor
- Evergreen Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Vanderbilt University Medical Center
- First posted
- Dec 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Neuropsychiatric systemic lupus erythematosus with cognitive impairment (NPSLE-CI) is a serious, disabling, and potentially life-threatening manifestation of SLE, affecting up to 80% of patients with cognitive impairments ("brain fog"), leading to substantial disability, approximately 2 times higher unemployment risk, reduced health-related quality of life (HRQoL), and mortality 2-14 times higher than the general population (standardized mortality ratio, SMR). No approved therapies exist for NPSLE cognitive dysfunction, representing a high-priority unmet need for this FDA-recognized serious condition with major functional and psychosocial burden. The objective of this study is to evaluate the safety, tolerability and efficacy of EG-501 in a precise patient subset with NPSLE. Participants will complete a full 14-week clinical trial, receiving either EG-501 or a placebo.
Conditions
- Neuropsychiatric Systemic Lupus Erythematosus
- Systemic Lupus Erythematosus (SLE)
- Cognitive Impairment
Interventions
PlaceboDrug
The placebo will match the study drug in appearance, dose, and frequency. It will not contain any active drug (EG-501).
EG-501Drug
EG-501/ EG-MNTP-01 is an oral, low-affinity NMDA receptor antagonist.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Repeatable Battery for Assessment of Neuropsychological Status (RBANS) Total Index Score at endpoint (Visit 4)Time frame: 12 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Cleveland Clinic
Cleveland, Ohio
Vanderbilt University Medical Center
Nashville, Tennessee
UT Health Houston
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.